Medical professionals have developed an alternative diagnostic approach to body mass index that aims to reduce misidentification of obesity in large population groups. The traditional BMI calculation, which divides weight in kilograms by height in metres squared, has long been criticized by experts as an imprecise tool for determining whether individuals have harmful levels of excess body fat.
The new method incorporates waist measurements, waist-to-height ratios, and assessments of organ function alongside BMI calculations. According to researchers, the current BMI-based approach fails to identify obesity in 5-9% of adults while incorrectly diagnosing the condition in up to 3% of the population. When scaled globally, these percentages translate to tens of millions of people receiving inaccurate diagnoses. Francisco Rubino, a professor of metabolic and bariatric surgery at King’s College London, noted that this misclassification represents a significant challenge both for public health and individual patient care.
The research team analyzed health records spanning 800,000 individuals from the United Kingdom, United States, China, and Spain, tracking their health outcomes over periods extending up to 15 years. Under the revised framework, individuals with a BMI exceeding 40 are classified as obese. Those with lower BMI values undergo additional screening based on waist circumference measurements. The approach also distinguishes between clinical obesity, where excess body fat actively impairs organ function, and pre-clinical obesity, where excess fat poses future health risks but has not yet caused measurable dysfunction.
When applied to the research population, obesity prevalence showed only modest increases under the new definition. Notably, only 5-10% of the broader population was identified as having clinical obesity accompanied by substantially elevated mortality risk. The revised diagnostic framework allows clinicians to differentiate health outcomes among individuals with identical BMI values. Approximately 80-90% of those identified with pre-clinical obesity did not develop clinical obesity within the subsequent 10-year period, according to study findings.
Rubino emphasized that personalized individual-level assessment for obesity could enable more precise clinical interventions, whether through lifestyle modifications, pharmaceutical treatments such as GLP-1 weight loss medications, or surgical procedures. He stated that implementing this approach in clinical practice would optimize treatment strategies and improve resource allocation.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI